153 related articles for article (PubMed ID: 37070541)
1. Mortality in hepatitis C virus-cured vs. hepatitis C virus-uninfected people with HIV.
Requena MB; Grabar S; Lanoy E; Pialoux G; Billaud E; Duvivier C; Merle P; Piroth L; Tattevin P; Salmon D; Weiss L; Costagliola D; Lacombe K
AIDS; 2023 Jul; 37(8):1297-1306. PubMed ID: 37070541
[TBL] [Abstract][Full Text] [Related]
2. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
[TBL] [Abstract][Full Text] [Related]
3. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
4. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity.
Falade-Nwulia O; Lesko CR; Fojo AT; Keruly JC; Moore RD; Sutcliffe CG; Mehta SH; Chander G; Thomas DL; Sulkowski M
J Infect Dis; 2024 Mar; 229(3):775-779. PubMed ID: 37793170
[TBL] [Abstract][Full Text] [Related]
6. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
7. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
[TBL] [Abstract][Full Text] [Related]
8. Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after antiretroviral therapy initiation.
Chalouni M; Trickey A; Ingle SM; Sepuvelda MA; Gonzalez J; Rauch A; Crane HM; Gill MJ; Rebeiro PF; Rockstroh JK; Franco RA; Touloumi G; Neau D; Laguno M; Rappold M; Smit C; Sterne JAC; Wittkop L;
AIDS; 2023 Aug; 37(10):1573-1581. PubMed ID: 37199601
[TBL] [Abstract][Full Text] [Related]
9. Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands.
Isfordink CJ; Smit C; Boyd A; de Regt MJA; Rijnders BJA; van Crevel R; Ackens RP; Reiss P; Arends JE; van der Valk M;
AIDS; 2022 May; 36(6):773-783. PubMed ID: 34999607
[TBL] [Abstract][Full Text] [Related]
10. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
[TBL] [Abstract][Full Text] [Related]
11. Alcohol consumption upon direct-acting antiviral therapy for hepatitis C among persons with human immunodeficiency virus in the United States.
Chen PH; Yenokyan K; Fojo AT; Hutton HE; Lesko CR; McCaul ME; Yang C; Cachay ER; Crane HM; Jacobson JM; Kim HN; Kitahata MM; Mayer KH; Moore RD; Napravnik S; Saag M; Lau B; Chander G
Drug Alcohol Depend; 2022 Dec; 241():109673. PubMed ID: 36332596
[TBL] [Abstract][Full Text] [Related]
12. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection.
Yin X; Kong L; Du P; Jung J
AIDS Care; 2022 Oct; 34(10):1330-1337. PubMed ID: 34581640
[TBL] [Abstract][Full Text] [Related]
13. The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences.
Fursa O; Mocroft A; Lazarus JV; Amele S; Lundgren J; Matulionyte R; Rasmussen LD; Rockstroh JK; Parczewski M; Jilich D; Moreno S; Vassilenko A; Lacombe K; Wandeler G; Borodulina E; Brännström J; Wiese L; Orkin C; Behrens GMN; Mansinho K; Portu JJ; Peters L;
AIDS; 2022 Mar; 36(3):423-435. PubMed ID: 34690281
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
15. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
16. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D;
HIV Med; 2021 Oct; 22(9):791-804. PubMed ID: 34212476
[TBL] [Abstract][Full Text] [Related]
17. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
[TBL] [Abstract][Full Text] [Related]
18. Low Spontaneous Clearance Rates of Recently Acquired Hepatitis C Virus in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men (PROBE-C Study).
Monin MB; Ingiliz P; Lutz T; Scholten S; Cordes C; Martínez-Rebollar M; Spinner CD; Nelson M; Rausch M; Bhagani S; Peters L; Reiberger T; Mauss S; Rockstroh JK; Boesecke C;
Clin Infect Dis; 2023 Feb; 76(3):e607-e612. PubMed ID: 36004410
[TBL] [Abstract][Full Text] [Related]
19. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
20. Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.
Baumann L; Braun DL; Cavassini M; Stoeckle M; Bernasconi E; Schmid P; Calmy A; Haerry D; Béguelin C; Fux CA; Wandeler G; Surial B; Rauch A
Liver Int; 2024 Jan; 44(1):169-179. PubMed ID: 37850685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
